



An estimated  
**6.1M**  
people do not know  
that they are living  
with HIV<sup>1</sup>



Globally **9.5M**  
people are awaiting  
treatment<sup>1</sup>



**5.8M out of 37.7M**  
people living with HIV  
around the world  
are in Asia<sup>1,2</sup>



In 2020, **240,000**  
**out of 1.5M** people  
newly infected with HIV  
came from Asia<sup>1,2</sup>



**3.7M**  
people living with HIV  
in Asia are under  
antiretroviral therapy<sup>1,2</sup>



# CREATING A HEALTHIER WORLD

**Together, we can end the epidemic  
for everyone, everywhere.**

Decades of scientific innovation, community partnership and public health advocacy have helped to transform HIV into a preventable, chronic condition for millions of people.

Although new infections have declined by 31% overall between 2010 and 2020, progress against HIV in Asia continues to be uneven.<sup>3</sup> Notably, 1 in 6 (or 5.8 million out of 37.7million) new HIV infections globally is found in Asia.<sup>1</sup> Declining political commitment alongside punitive laws, rising stigma and discrimination, continue to be barriers to effective HIV responses.<sup>3</sup>

Gilead is committed to support UNAIDS's targets to end the HIV epidemic by 2030. To do this we will continue to advance scientific innovation and transformative collaboration to support the wellness of all people impacted by HIV until the virus is eliminated.

<sup>1</sup> UNAIDS (July 2021). Factsheet – World AIDS Day 2021.

[https://www.unaids.org/sites/default/files/media\\_asset/UNAIDS\\_FactSheet\\_en.pdf](https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf)

<sup>2</sup> For the purpose of this fact sheet, and the statistics contained, the term Asia refers to the 38 countries including South-East Asia and Western Pacific regions as designated by UNAIDS. Asia and the Pacific.

<sup>3</sup> UNAIDS (July 2021). UNAIDS Global AIDS Update 2021.

<https://www.aidsdatahub.org/sites/default/files/resource/unaids-global-aids-update-2021.pdf>

# OUR COMMITMENT TO END THE HIV EPIDEMIC



**Recognized as the #1 global philanthropic funder of HIV-related programs in 2022** - *Top 3 philanthropic funders of HIV-related programs in East Asia and Southeast Asia*



## Developing Life-Changing Innovations

- Gilead helped transform HIV care by developing the first HIV single tablet regimen and pioneering the first oral therapy to prevent HIV. Today, our scientific innovation helps address the diverse needs of people and communities affected by HIV worldwide.
- We are committed to delivering innovative therapies that have the potential to address unmet needs in HIV treatment and prevention and are actively pursuing research that could, one day, lead to a cure.
- To optimize the tools we have today and innovate to bring forward new, novel and groundbreaking solutions, the Gilead HIV Research Scholars Program offers research grants of up to US\$130,000 to junior faculty researchers for a 2-year period.
- We also foster ongoing HIV education by supporting national, regional and international<sup>4</sup> medical and HIV conferences.



## Advancing Equitable Care to Optimize Health Outcomes

- Our dedication to innovation applies not only to how we approach making medicine, but to how we aim to support systems and policies that help facilitate broader access to medicines.
- To understand the specific needs of those disproportionately impacted by HIV and underrepresented in existing studies, we conducted [pulse surveys](#) across the region in 2020 to assess the critical gaps in access to HIV care services due to the COVID-19 pandemic.
- Partnerships are critical to end the HIV epidemic. In 2021, we pioneered the first [HIV Community Masterclass Series Asia](#) with the APCOM Foundation to bring together regional experts for dialogue and knowledge-exchange to accelerate HIV elimination in local communities.



## Transformative Collaboration to Help End HIV for All

Gilead works with partners in Asia to reduce disparities across HIV care and prevention, supporting local communities we operate in.



### Gilead Asia Pacific Rainbow Grant

- Launched in 2018, the [Gilead Asia Pacific Rainbow Grant](#) has supported more than 112 impactful projects by awarding US\$4.5 million in grant funding to NGOs across Asia Pacific. Initiatives being supported range from disease education, digital engagement, support against stigma and discrimination to capacity building.



### Me and My Healthcare Provider Campaign

- The [campaign](#) promotes best practice in healthcare service delivery by championing frontline healthcare workers who deliver stigma-free HIV care. In 2021, we partnered with the International AIDS Society to expand the campaign to two locations in Asia: Hong Kong; and Taiwan and renew the program in Latin America: Brazil and Mexico.

### Enhancing HIV Prevention in Asia

- Since 2018, we have partnered with local health authorities, NGOs and academic institutions to increase access to HIV medication for key populations in Taiwan, Hong Kong, and South Korea through demonstration projects. Data from these projects help health authorities and the community develop effective HIV prevention strategies.

### Championing Diversity and Inclusion

- Since 2018, we have been marching at the annual Taipei Pride Parade and supporting numerous LGBTQ+ celebrations across Asia.
- In 2021, we were awarded the Bronze Standard in the Hong Kong LGBT+ Inclusion Index, acknowledging the progress of our LGBT+ inclusion journey.
- We are proud to be an official supporter and sponsor for the first Gay Games to be held in Asia. Themed “Unity in Diversity”, Gay Games Hong Kong 2023 marks our like-minded commitment to create equitable opportunities for all in the communities we serve.

<sup>4</sup> Singapore AIDS Conference, AIDS Concern HIV Conference, Taiwan AIDS Society Annual Meeting, China National AIDS Conference.